Literature DB >> 12875918

Expression and distribution of a small-conductance calcium-activated potassium channel (SK3) protein in skeletal muscles from myotonic muscular dystrophy patients and congenital myotonic mice.

Takashi Kimura1, Masanori P Takahashi, Harutoshi Fujimura, Saburo Sakoda.   

Abstract

The SK3 channel, a small-conductance calcium-activated potassium channel, is expressed in immature fibers of skeletal muscle and becomes down regulated after innervation. We have previously shown that the level of mRNA of the SK3 channel is increased in muscle from myotonic dystrophy. In this study, we have carried out an immunohistochemical study using a polyclonal anti-SK3 antibody. SK3 protein is partly expressed at the cell membrane of normal sized fibers in myotonic dystrophy. Although SK3 channels are also expressed in muscles from polymyositis and amyotrophic lateral sclerosis, the positive staining is observed only in regenerating or denervated fibers. No expression of SK3 protein in a myotonic mouse (ADR) suggests that the increase in the SK3 channel in myotonic dystrophy is not due to hyperexcitability. These data support the hypothesis of a differentiation defect in myotonic dystrophy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12875918     DOI: 10.1016/s0304-3940(03)00638-4

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  7 in total

1.  Muscle chloride channel dysfunction in two mouse models of myotonic dystrophy.

Authors:  John D Lueck; Ami Mankodi; Maurice S Swanson; Charles A Thornton; Robert T Dirksen
Journal:  J Gen Physiol       Date:  2006-12-11       Impact factor: 4.086

Review 2.  Myotonic Dystrophy Type 1 Management and Therapeutics.

Authors:  Cheryl A Smith; Laurie Gutmann
Journal:  Curr Treat Options Neurol       Date:  2016-12       Impact factor: 3.598

3.  Analysis of Single Nucleotide Polymorphisms (SNPs) of the small-conductance calcium activated potassium channel (SK3) gene as genetic modifier of the cardiac phenotype in myotonic dystrophy type 1 patients.

Authors:  F Rinaldi; A Botta; L Vallo; G Contino; A Morgante; R Iraci; C Catalli; G Silvestri; V M Ventriglia; L Politano; G Novelli
Journal:  Acta Myol       Date:  2008-12

4.  Systems analysis of transcriptional data provides insights into muscle's biological response to botulinum toxin.

Authors:  Kavitha Mukund; Margie Mathewson; Viviane Minamoto; Samuel R Ward; Shankar Subramaniam; Richard L Lieber
Journal:  Muscle Nerve       Date:  2014-03-17       Impact factor: 3.217

5.  Fibroblast growth factor 19 as a countermeasure to muscle and locomotion dysfunctions in experimental cerebral palsy.

Authors:  Sabrina da Conceição Pereira; Bérengère Benoit; Francisco Carlos Amanajás de Aguiar Junior; Stéphanie Chanon; Aurélie Vieille-Marchiset; Sandra Pesenti; Jérome Ruzzin; Hubert Vidal; Ana Elisa Toscano
Journal:  J Cachexia Sarcopenia Muscle       Date:  2021-10-26       Impact factor: 12.910

6.  Novel transcriptional profile in wrist muscles from cerebral palsy patients.

Authors:  Lucas R Smith; Eva Pontén; Yvette Hedström; Samuel R Ward; Henry G Chambers; Shankar Subramaniam; Richard L Lieber
Journal:  BMC Med Genomics       Date:  2009-07-14       Impact factor: 3.063

7.  Subcellular expression and neuroprotective effects of SK channels in human dopaminergic neurons.

Authors:  A M Dolga; A de Andrade; L Meissner; H-G Knaus; M Höllerhage; P Christophersen; H Zischka; N Plesnila; G U Höglinger; C Culmsee
Journal:  Cell Death Dis       Date:  2014-01-16       Impact factor: 8.469

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.